Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265249 | 0.78 | HTR2A (0.46) | HTR2AHTTRAB9AL3MBTL1CA1 | |
| SCHEMBL17662368 | 0.77 | IDO1 (0.59) | IDO1AKR1C3HTR2AMAOBLOXL2 | |
| SCHEMBL8424295 | 0.74 | IDO1 (0.56) | IDO1AKR1C3HTR2AMAOBLOXL2 | |
| SCHEMBL16978750 | 0.74 | IDO1 (0.56) | IDO1AKR1C3HTR2AMAOBLOXL2 | |
| SCHEMBL20905140 | 0.74 | IDO1 (0.51) | IDO1AKR1C3HTR2AMAOBLOXL2 | |
| SCHEMBL29143227 | 0.74 | IDO1 (0.59) | IDO1AKR1C3MAOBLOXL2RAB9A | |
| SCHEMBL6141234 | 0.72 | IDO1 (0.53) | IDO1AKR1C3HTR2AMAOBLOXL2 | |
| SCHEMBL7087223 | 0.72 | IDO1 (0.61) | IDO1AKR1C3MAOBLOXL2RAB9A | |
| SCHEMBL17636185 | 0.72 | IDO1 (0.61) | IDO1AKR1C3MAOBLOXL2RAB9A | |
| SCHEMBL27818391 | 0.72 | IDO1 (0.61) | IDO1AKR1C3MAOBLOXL2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569536-B2 | C-nitroso-derived nitroxyl donors | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130040919-A1 | C-NITROSO-DERIVED NITROXYL DONORS | KING S BRUCE (US) | 2013-02-14 | — | — | US | disclosed |
| US-8269034-B2 | C-nitroso-derived nitroxyl donors | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110263674-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-27 | — | — | US | disclosed |
| US-7989652-B2 | C-nitroso-derived nitroxyl donors | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100173970-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-08 | — | — | US | disclosed |
| US-7696373-B2 | C-nitroso-derived nitroxyl donors | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090137668-A1 | C-NITROSO-DERIVED NITROXYL DONORS | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2009-05-28 | — | — | US | disclosed |
| EP-2010476-A2 | C-NITROSO-DERIVED NITROXYL DONORS | Wake Forest University Health Sciences (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120839-A2 | C-NITROSO-DERIVED NITROXYL DONORS | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263674-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NOS1, NOS2, NOS3 | IDO1 352/4885AKR1C3 48/4885HTR2A 2011/4885 |
| US-20130040919-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NOS1, NOS2, NOS3 | IDO1 352/4885AKR1C3 48/4885HTR2A 2011/4885 |
| US-20100173970-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NOS1, NOS2, NOS3 | IDO1 352/4885AKR1C3 48/4885HTR2A 2011/4885 |
| US-20090137668-A1 | C-NITROSO-DERIVED NITROXYL DONORS | NOS1, NOS2, NOS3 | IDO1 372/4885AKR1C3 40/4885HTR2A 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.